TetraStem, Lead Product of ViaDerma, Inc., Hopes to Slow Rates of Diabetic Amputations

LOS ANGELES, Nov. 7, 2014 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that has shown success in aiding the healing of diabetic wounds and therefore preventing amputations.

Diabetes is a serious medical condition that affects how the body uses blood sugar. Because glucose is vital for your cells to have enough energy, too much of it can lead to major medical problems such as amputations. In 2010, roughly 8% of the American population had diabetes, or 25.8 million people. Of those 25.8 million diagnosed diabetics, 73,000 adults had non-traumatic lower-limb amputations, according to the American Diabetes Association.

TetraStem has shown success in laboratory trials and found to be 99 percent effective against all bacteria. ViaDerma believes the application of TetraStem can maximize the healing of diabetic wounds before they require amputation.

"TetraStem kills infection because of the proprietary, transdermal delivery that allows TetraStem to kill bacteria chemically and physically," says CEO of ViaDerma, Dr. Christopher Otiko. "We hope that the application of TetraStem can help reduce the number of amputations from diabetic wounds, thereby saving lives and increasing people's quality of life."

About ViaDerma, Inc.

Founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (OTCQB:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit www.viadermalicensing.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in our filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.